Part of Clavicular's Looksmaxxing Stack
The bulk option for Retatrutide — Clavicular's primary looksmaxxing peptide. Best value for extended research protocols.
Research Specifications
- IUPAC Name:
- Retatrutide (LY3437943)
- CAS Number:
- 2381089-83-2
- Molecular Weight:
- 4571.2 Da
- Form:
- Lyophilized powder
- Purity:
- ≥98% (HPLC verified)
- Storage:
- −20°C long-term / 4°C up to 4 weeks reconstituted
- Reconstitution:
- Bacteriostatic water
- Price per mg:
- $11.67
GLP-3 R 30mg
Triple GLP-1/GIP/glucagon receptor agonist. The highest mean weight reduction of any peptide in Phase 2 clinical trials — 24.2% at 12mg.
Featured in Clavicular's looksmaxxing protocol
−24.2%
Mean Weight Reduction
Phase 2, 12mg dose (NEJM 2023)
3 receptors
Simultaneous Targets
GLP-1 / GIP / Glucagon
4571 Da
Molecular Weight
NCBI PubChem
Receptor Targets
Why Clavicular Uses This Peptide
The bulk option for Retatrutide — Clavicular's primary looksmaxxing peptide. Best value for extended research protocols.
See Clavicular's complete looksmaxxing stack →Triple Receptor Agonism: GLP-1, GIP & Glucagon
Retatrutide (LY3437943) is a synthetic once-weekly peptide that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. GLP-1 agonism reduces appetite and slows gastric emptying. GIP agonism enhances insulin secretion and may directly promote adipocyte lipolysis. Glucagon receptor agonism directly stimulates hepatic fat oxidation and thermogenesis — making Retatrutide the only triple-agonist in its class. This multi-receptor approach produced the largest mean weight reduction of any peptide published to date.
Research Highlights
Phase 2 NEJM Trial (2023)
338 participants with obesity, 48-week double-blind RCT. The 12mg dose group achieved −24.2% mean body weight reduction vs −2.1% placebo. Importantly, the weight loss trajectory had not plateaued at 48 weeks, suggesting continued efficacy beyond the trial period. Published in the New England Journal of Medicine.
Visceral vs. Subcutaneous Fat
Retatrutide's glucagon component drives preferential visceral adipose tissue (VAT) reduction — the metabolically harmful deep abdominal fat linked to cardiovascular disease and insulin resistance. This VAT selectivity distinguishes it from GLP-1 only agonists in research contexts.
Lean Mass Preservation
Analysis of body composition data from the Phase 2 trial showed a higher proportion of fat mass loss vs. lean mass loss compared to diet-alone controls, consistent with the GIP receptor's role in adipocyte-specific lipolysis and the preservation of muscle protein.
Research FAQ
What is Retatrutide 30mg used for in research?
How does Retatrutide compare to Tirzepatide and Semaglutide?
Why does Clavicular use Retatrutide specifically?
What is the price per mg for the 30mg vial?
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| Apollo (via ClavTides) | >98% HPLC | $349.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
More from Clav's Stack
GLP-2 T 30mg
Tirzepatide is a synthetic multi-receptor peptide analog consisting of 39 amino acids with lipidation to enhance stability. Supplied as a lyophilized powder for laboratory research applications.
GLP-3 R 10mg
Retatrutide is a synthetic peptide analog incorporating structural modifications designed to enhance stability. Supplied as lyophilized powder for laboratory research applications.
GLP-3 R 15mg
Retatrutide is a synthetic peptide analog incorporating structural modifications designed to enhance stability. Supplied as lyophilized powder for laboratory research applications.
GLP-3 R 30mg
$349.99